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sheffield.ac.ukSummarySecondary amenorrhoea and galactorrhoea represent a common endocrine presentation. We report a case of an oestrogen-
producing juvenile granulosa cell tumour (JGCT) of the ovary in a 16-year-old post-pubertal woman with hyperprolacti-
naemia amenorrhoea and galactorrhoea which resolved following surgical resection of the tumour. This patient presented
with a 9-month history of secondary amenorrhoea and a 2-month history of galactorrhoea. Elevated serum prolactin at
7081 mIU/l and suppressed gonadotropins (LH !0.1 U/l; FSH !0.1 U/l) were detected. Serum oestradiol was significantly
elevated at 7442 pmol/l with undetectable b-human chorionic gonadotropin. MRI showed a bulky pituitary with no visible
adenoma. MRI of the abdomen showed a 4.8 cm mass arising from the right ovary with no evidence of metastatic disease.
Serum inhibin B was elevated at 2735 ng/l. A right salpingo-oophorectomy was performed, and histology confirmed the
diagnosis of a JGCT, stage International Federation of Gynaecology and Obstetrics 1A. Immunohistochemical staining for
prolactin was negative. Post-operatively, oestrogen and prolactin levels were normalised, and she subsequently had a
successful pregnancy. In summary, we present a case of an oestrogen-secreting JGCT with hyperprolactinaemia manifesting
clinically with galactorrhoea and secondary amenorrhoea. We postulate that observed hyperprolactinaemia was caused
by oestrogenic stimulation of pituitary lactotroph cells, a biochemical state analogous to pregnancy. To the best of our
knowledge, this is the first report of hyperprolactinaemia as a result of excessive oestrogen production in the context
of a JGCT.Learning points:
† Hyperprolactinaemia with bilateral galactorrhoea and secondary amenorrhoea has a wide differential diagnosis and
is not always caused by a prolactin secreting pituitary adenoma.
† Significantly elevated serum oestradiol levels in the range seen in this case, in the absence of pregnancy,
are indicative of an oestrogen-secreting tumour.
† JGCTs are rare hormonally active ovarian neoplasms mostly secreting steroid hormones.
† Serum inhibin can be used as a granulosa cell-specific tumour marker.
† JGCTs have an excellent prognosis in the early stages of the disease.http://www.edmcasereports.com
Published by Bioscientifica Ltd.
A Iqbal, P Novodvorsky
and others
JGCT of the ovary with
hyperprolactinaemia
ID: 16-0006; March 2016
DOI: 10.1530/EDM-16-0006Background
Hyperprolactinaemia constitutes a common endocrine
presentation. The commonest causes of symptomatic non-
physiological hyperprolactinaemia are prolactinomas,
other pituitary and parasellar tumours, medication use,
renal failure and hypothyroidism. Clinically, hyperpro-
lactinaemia typically presents with galactorrhoea, hypo-
gonadism and infertility (1). Treatment depends on the
underlying aetiology and may simply involve withdrawal
of the causative agent or treatment of the causative
endocrine condition. In the case of pituitary or para-
pituitary lesions, treatment may include a dopamine
agonist therapy, surgery or radiotherapy (1).
Ovarian granulosa cell tumours are rare hormonally
active neoplasms accounting for w3–5% of all ovarian
cancers (2). Juvenile granulosa cell tumours (JGCTs) of the
ovary are considered to be more aggressive than the adult
type but also far less common, representing only 5% of all
granulosa cell tumours in the paediatric age group (3) (4).
Granulosa cell tumours secrete steroid hormones – mostly
oestrogens and less commonly androgens and progestins (2),
but secretion of prolactin (5) and insulin (6) has been
described. Most granulosa cell tumours secrete inhibin
which has been used as granulosa cell-specific tumour
marker (7). Tumour staging uses the International Federation
of Gynaecology and Obstetrics (FIGO) system. Most JGCTs
are FIGO stage 1 at the time of diagnosis and have excellent
cure rates (5-year survival rate 90–95%) with surgery being
the mainstay of therapy. Advanced stages bear a worse
prognosis (5-year survival rate 25–50%) and require adjuvant
chemotherapy with cisplatin-based regimens (8).Figure 1
(A) An MRI of the pituitary with contrast, T1-weigthed image, coronal view.
The pituitary is enlarged and bulges into the suprasellar cistern
(black arrow), but there is no evidence of micro or macroadenoma.
(B) MRI of the abdomen with contrast (sagittal view) showed a 4.8 cm
rounded mass within the right ovary (white arrow) and normal
appearances of the uterus and left ovary.Case presentation
A 16-year-old Eastern European Romani woman (nulligra-
vida and nullipara) presented with a 9-month history of
secondary amenorrhoea and a 2-month history of bilateral
galactorrhoea. She denied headache or any visual symp-
toms. Her past medical history was unremarkable with
menarche at age 14 and a previously normal menstrual
cycle. She was not taking any regular medications apart
from paracetamol and ibuprofen over the counter. She had
never used hormonal contraception. On examination,
visual fields were full on confrontation and cranial nerves
were intact. The thyroid was not palpable, and there were
no signs of androgen hormone excess. The remainder of
the external examination was unremarkable. She was a
cigarette smoker (5/day) and denied alcohol consumption
and substance misuse.http://www.edmcasereports.comInvestigation
Anterior pituitary function assessment revealed markedly
elevated serum prolactin at 7081 mIU/l (reference range
102–496 mIU/l) with negative macroprolactin screen and
fully suppressed gonadotropins (luteinising hormone (LH)
!0.1 U/l; follicle-stimulating hormone (FSH) !0.1 U/l).
Thyrotrophin (TSH) was 3.3 mIU/l (3.9–7.7 mIU/l), free T4
borderline low at 11.5 pmol/l (12.0–22.0 pmol/l), IGF1
low at 129 mg/l (270–660 mg/l) and adrenocorticotrophin
(ACTH) was normal at 21.1 ng/l (reference range at 0900 h
!46 ng/l). Serum oestradiol was significantly elevated
at 7442 pmol/l with undetectable b-human chorionic
gonadotropin (b-hCG). Serum testosterone was borderline
elevated at 2.0 nmol/l (0.3–1.7 nmol/l) together with
elevated SHBG at O200 nmol/l (32.4–128 nmol/l).
Although prolactin levels O5000 mU/l usually indicate
the presence of a macroprolactinoma (after exclusion of
pregnancy and medication-induced hyperprolactinaemia)
(1), MRI of the pituitary with contrast showed an enlarged
anterior pituitary with a convex upper border, but no
micro or macroadenoma was visible (Fig. 1A).
Given the highly elevated serum oestradiol levels and
negative pregnancy test, we considered an ovarian lesion
as a source of oestrogens driving lactotroph hyperplasia
and prolactin secretion – a state analogous to normal
pregnancy. MRI of the abdomen and pelvis showed a
4.8 cm mass within the right ovary and normal appearan-
ces of the uterus and left ovary (Fig. 1B). Serum inhibin B
levels were elevated at 2735 ng/l (reference range !341 ng/l
in premenopausal women) indicating a presence of a
granulosa cell tumour of the ovary (7). Other tumour2
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5–160 ng/l), CA 125 (20 U/ml; reference range 0–30 U/ml)
and a-fetoprotein (1.21 mg/l; reference range !8 mg/l) were
negative.Treatment
The patient underwent an uneventful right salpingo-
oophorectomy, and histology confirmed a JGCT of the
right ovary which was staged as FIGO 1A (Fig. 2A).
Immunohistochemical analysis of the JGCT specimen
was negative for prolactin (Fig. 2B).Outcome and follow-up
This patient defaulted from endocrine follow-up after
surgery. However, she conceived 6 months after the
surgery and gave birth to a healthy child. A hormonal
profile requested by the patient’s general practitioner
2 years after surgery showed a normal oestradiol of
821 pmol/l and normal prolactin of 327 mIU/l. At the
time of writing this report, the patient is pregnant with
her second child.Figure 2
(A) JGCT of the right ovary, FIGO stage 1A. Hematoxylin and eosin
staining shows mostly luteinised cells with clear or pale eosinophilic
cytoplasm and scattered irregular follicular spaces. (B) Prolactin immuno-
histochemistry did not identify any significant expression of prolactin
within the tumour cells.
http://www.edmcasereports.comDiscussion
We present a case of an oestrogen-secreting JGCT in a
16-year-old woman resulting in hyperprolactinaemia and
presenting clinically with galactorrhoea and secondary
amenorrhoea. This situation, to an extent, resembles
normal pregnancy in which prolactin levels increase
approximately tenfold (9) and the pituitary increases in
volume more than twofold as a result of oestrogenic stimu-
lation of lactotrophs (10). Surgical removal of the ovarian
neoplasm resulted in restoration of fertility as evidenced
by the patient’s pregnancy 6 months after surgery.
An FSH-producing pituitary adenoma presenting with
ovarian hyperstimulation syndrome (OHSS), oligomenor-
rhoea and bilateral galactorrhoea with elevated FSH,
oestradiol and prolactin levels has been previously
reported (11). Subsequent transsphenoideal surgery of
the pituitary macroadenoma resulted in normalisation
of hormonal values and resolution of symptoms. Absence
of pituitary lesion on MRI and suppressed FSH levels
exclude this clinical scenario in the presented case.
To the best of our knowledge, this is the first report of
hyperprolactinaemia as a result of excessive oestrogen
production in the context of a JGCT. A Finnish group
reported of an aggressive JGCT in a 19-year-old woman
secreting prolactin but not oestrogen (5) – a scenario
which we managed to exclude by the negative immuno-
histochemical analysis for prolactin in the JGCT speci-
men. An Italian group reported a JGCT (FIGO stage 1A)
in a 16-year-old woman who presented with secondary
amenorrhoea (6). Elevated levels of prolactin (approxi-
mately twofold of the upper limit of normal) were
detected, but oestradiol levels were normal. The JGCT
specimen stained negatively for prolactin, and serum
prolactin levels did not normalise following the surgery
making it difficult to link the mild hyperprolactinaemia to
the presence of the tumour.
JGCTs producing oestradiol, 17-hydroxyprogesterone,
DHEA and testosterone were reported in two 16-month
old girls presenting with several signs of ‘precocious
puberty’ – transient vaginal bleeding, pubic hair, clitor-
omegaly and breast enlargement which all regressed
following surgical removal of the tumour (3). Several
cases of JGCTs producing oestradiol were reported in older
age groups (4). Of 33 cases of JGCTs, 14 presented with
pseudo-precocious puberty and elevated oestradiol levels.
In seven of these patients, oestradiol was also measured
after surgery and returned to normal levels in all cases (4).
However, prolactin and inhibin levels were not measured
in any of these patients.3
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We describe a case of an oestrogen-secreting JGCT with
marked hyperprolactinaemia presenting clinically with
galactorrhoea and secondary amenorrhoea. Based on
immunohistochemistry of the JGCT specimen, we postu-
late that the observed hyperprolactinaemia was caused by
oestrogenic stimulation of pituitary lactotroph cells, a
biochemical state analogous to pregnancy. Our case thus
illustrates a case of tumour-induced hyperprolactinaemia
with a pathophysiology that has not been previously
reported in the literature and is currently not reflected in
clinical practice guidelines (1).Declaration of interest
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